Science AI Journal
Medicine · Research topic

Open research questions in Rheumatoid Arthritis Research and Therapies

264 unresolved questions extracted from the limitations and future-work sections of 824 Rheumatoid Arthritis Research and Therapies papers in our library. Each links back to the study that raised it.

What the literature leaves open

  • The role and mechanism of FSCN1 in FLS phenotypic activation remain unclear - The study aims to fill this gap by analyzing FSCN1 expression and determining its underlying mechanism

    FSCN1 Promotes Rheumatoid Arthritis Progression via Inhibiting TRIM38–Mediated Ubiquitination of IGF2BP1 in Fibroblast‐Like Synoviocytes · 2026 · DOI

  • Detailed information regarding lesion morphology, anatomical distribution, time to onset, duration, and resolution was frequently unavailable, - The review was limited to peer-reviewed studies reporting oral ulceration, stomatitis, aphthous ulceration, or related oral mucosal events in adults receiving TCZ, - The study was a scoping review and did not provide a quantitative synthesis of the results

    Tocilizumab-associated oral ulcerations: a case report and scoping review · 2026 · DOI

  • Further studies are needed to characterize the clinical characteristics, frequency, and relationship to treatment of oral ulcerative events, - Research should focus on the mechanisms underlying the development of oral ulcerations in patients treated with TCZ, - Studies should investigate the impact of oral ulcerations on the quality of life of patients treated with TCZ

    Tocilizumab-associated oral ulcerations: a case report and scoping review · 2026 · DOI

  • The disease-associated immunometabolic states of macrophages in RA and OA remain incompletely understood. There is a need to distinguish the inflammatory processes underlying RA and OA. A better mechanistic understanding of disease-associated myeloid responses is required.

    Patient-Derived Transcriptomics Reveals Distinct Associated IFNγ-Myeloid States and Mitochondrial Complex I Programs in Rheumatoid Arthritis and Osteoarthritis · 2026 · DOI

  • The study had a small sample size (n=39), - The study only investigated patients with seropositive RA, - The molecular simulations were limited to three temperatures (30 °C, 37 °C, and 50 °C)

    Monomeric CRP is prevalent in the blood of patients with rheumatoid arthritis and correlates with clinically relevant markers · 2026 · DOI

  • Further studies are needed to investigate the role of mCRP in RA, - Studies should be conducted to develop clinical assays that can distinguish between pCRP and mCRP, - Research should be done to explore the potential therapeutic applications of mCRP

    Monomeric CRP is prevalent in the blood of patients with rheumatoid arthritis and correlates with clinically relevant markers · 2026 · DOI

  • further studies are needed to determine the effectiveness of different vaccines in patients with IRDs, - research on the impact of vaccination on COVID-19 outcomes in patients with IRDs is necessary

    COVID-19 outcomes in patients with inflammatory rheumatic diseases: associations with disease subtypes, treatments, and vaccination status · 2026 · DOI

  • Reverse causation is a major concern because chronic inflammation, disease duration, diet, comorbidity, and repeated exposure to DMARDs, glucocorticoids, antibiotics, proton pump inhibitors, and analgesics can all alter the microbiome. Methodological resolution is another constraint, as 16S rRNA sequencing characterizes taxonomic composition, while PICRUSt2 estimates rather than measures functional potential. The study is limited by its cross-sectional, single-sample design and the small number of patients with D2T RA.

    Gut dysbiosis in difficult-to-treat rheumatoid arthritis: hypothesized microbial endotypes, persistent inflammation, and pharmacological treatment resistance · 2026 · DOI

  • D2T RA-specific evidence is currently too limited to support a stable microbial biomarker, - the cross-sectional, single-sample design could not establish whether ecological differences preceded treatment failure, - reverse causation is a major concern due to various factors that can alter the microbiome

    Gut dysbiosis in difficult-to-treat rheumatoid arthritis: hypothesized microbial endotypes, persistent inflammation, and pharmacological treatment resistance · 2026 · DOI

  • Investigation of the causes of depression and anxiety in patients with rheumatic diseases, - Development of effective interventions to address depression and anxiety, - Study of the impact of depression and anxiety on disease activity and physical activity

    A comparative cross-sectional study of psychological distress, fatigue, and physical activity in patients with rheumatoid arthritis, systemic lupus erythematosus, and Sjögren's disease · 2025 · DOI

  • The prognostic value of hemoglobin levels at initial diagnosis of rheumatoid arthritis remains unknown. Identifying readily available clinical markers that reflect the inflammatory burden and predict long-term prognosis remains a critical unmet need.

    Prognostic role of baseline hemoglobin level for long-term mortality in newly diagnosed rheumatoid arthritis: a cohort study · 2025 · DOI

  • While some PAD histone citrullination sites are known, a comprehensive investigation of all histone tail arginines targeted by catalytically active PADs 1-4 is lacking.

    Differential histone tail citrullination by protein arginine deiminases observed via NMR spectroscopy · 2026 · DOI

  • , temporomandibular-joint involvement) was low; and (5) tailored information linking RA and oral health was scarce, and participants preferred clear guidance from clinicians while firmly rejecting oral hygiene guidance from friends and family.

    Understanding Rheumatoid Arthritis‐Oral Health Perceptions Around Diagnosis and the Early Disease Course: A Phenomenological Approach · 2026 · DOI

  • However, the effects of specific rheumatic disease subsets, treatment patterns, and vaccine types remain incompletely understood.

    COVID-19 outcomes in patients with inflammatory rheumatic diseases: associations with disease subtypes, treatments, and vaccination status · 2026 · DOI

  • However, the safety of different types of interleukin inhibitors used to treat RA has not been adequately evaluated.

    Comparative safety of interleukin inhibitors for rheumatoid arthritis: a systematic review and network meta-analysis of randomized controlled trials · 2026 · DOI

  • Taken together, this study provides a proof-of-concept for NTZ’s immunomodulatory activity in RA, yet the data remain insufficient for therapeutic claims and only lay the groundwork for further studies.

    Nitazoxanide alleviates collagen-induced arthritis by inhibiting STAT3-dependent Th17 cell differentiation and inflammatory cytokines production · 2026 · DOI

  • Nitazoxanide (NTZ), an FDA-approved anti-parasitic drug, has shown anti-inflammatory effects in rheumatoid arthritis (RA) fibroblast-like synoviocytes, yet its impact on immune cell function and its potential synergy with methotrexate (MTX) remains unclear.

    Nitazoxanide alleviates collagen-induced arthritis by inhibiting STAT3-dependent Th17 cell differentiation and inflammatory cytokines production · 2026 · DOI

  • ObjectivesFew studies have investigated health outcomes associated with arthritis in low-middle-income countries.

    Hospitalization and Mortality Among Mexican Adults With Arthritis: Findings From the Mexican Health and Aging Study · 2025 · DOI

  • While anemia commonly occurs in patients with RA and is associated with disease activity in established diseases, the prognostic value of hemoglobin levels at initial diagnosis remains unknown.

    Prognostic role of baseline hemoglobin level for long-term mortality in newly diagnosed rheumatoid arthritis: a cohort study · 2025 · DOI

  • Objectives Rheumatoid arthritis (RA) is associated with increased cardiovascular (CV) risk, yet the mechanisms remain unclear.

    Subclinical myocardial changes in rheumatoid arthritis: cardiovascular magnetic resonance evidence of immuno-inflammatory remodeling · 2025 · DOI

  • BACKGROUND AND OBJECTIVES: Rheumatoid arthritis (RA) has been linked to an increased risk of dementia, yet little is known about how RA affects the progression of cognitive impairment and the risk of mortality in people with dementia.

    Association of Rheumatoid Arthritis With Progression of Cognitive Impairment and Risk of Mortality in People With Dementia · 2025 · DOI

  • Future research should focus on improving access to non-pharmacological therapies and standardizing healthcare protocols for better patient outcomes.

    Healthcare Interventions in the Management of Rheumatic Diseases: A Narrative Analysis of Effectiveness and Emerging Strategies · 2025 · DOI

  • The etiology of RA has not yet been fully elucidated, but a large number of studies have shown that the initiation of inflammation in RA is closely related to T-cell activation, the production of a variety of pro-inflammatory cytokines, macrophage M1/M2 imbalance, homeostatic imbalance of the intestinal flora, fibroblast-like synoviocytes (FLSs) and synovial tissue macrophages (STMs) in the synovial lumen of joints that exhibit an aggressive phenotype.

    Resolution of inflammation during rheumatoid arthritis · 2025 · DOI

  • Information regarding gene expression of GZMs, PRF-1 and SRGN in synovium and blood pathotypes and their association with DAS28-ESR (Disease Activity Score-28 with erythrocyte sedimentation rate) and with DAS28-CRP (C-reactive protein) in Early RA (eRA) is lacking, as is the effect of RA drugs on these genes.

    Pathotype-Specific Expression of Granzyme-Perforin Pathway Genes and their Association with Clinical Disease Activity in Early Rheumatoid Arthritis and in a Randomized Clinical Trial 2923 · 2025 · DOI

  • The efficacy and safety profiles of subcutaneous tocilizumab monotherapy, tocilizumab combined with methotrexate, and methotrexate alone have not yet been evaluated in the same large-scale study.

    Tocilizumab Monotherapy or Combined With Methotrexate for Rheumatoid Arthritis · 2025 · DOI

Most-cited papers in Rheumatoid Arthritis Research and Therapies

Most recent work

Find a gap in your own Rheumatoid Arthritis Research and Therapies sub-topic

This page shows what the Rheumatoid Arthritis Research and Therapies literature already flags as unresolved. To narrow it to your specific question, run the guided finder — it searches the gap library on demand and checks candidates against 250M+ OpenAlex works.

Open the Research Gap Finder →

Related topics in Medicine

Artificial Intelligence in Healthcare and Education
2,044 open questions
Substance Abuse Treatment and Outcomes
1,964 open questions
Smoking Behavior and Cessation
990 open questions
Dementia and Cognitive Impairment Research
974 open questions
Innovations in Medical Education
960 open questions
Physical Activity and Health
923 open questions
Attention Deficit Hyperactivity Disorder
839 open questions
Schizophrenia research and treatment
709 open questions
264 open questions have been extracted from the limitations and future-work passages of 824 Rheumatoid Arthritis Research and Therapies papers in our library. Each one below links back to the study that raised it, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? A Tier 1–5 acceptance probability in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck prior-publication & salami-slicing risk across 8 sources.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.